Safety and Efficacy of Topical Loteprednol Etabonate 0.5%, Versus Prednisolone Acetate 1%, for the Treatment of Intraocular Inflammation Following Surgery for Childhood Cataract

Trial Profile

Safety and Efficacy of Topical Loteprednol Etabonate 0.5%, Versus Prednisolone Acetate 1%, for the Treatment of Intraocular Inflammation Following Surgery for Childhood Cataract

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 28 Apr 2017

At a glance

  • Drugs Loteprednol etabonate (Primary) ; Prednisolone acetate
  • Indications Ocular inflammation
  • Focus Therapeutic Use
  • Sponsors Bausch & Lomb
  • Most Recent Events

    • 25 Apr 2017 Planned End Date changed from 1 Dec 2017 to 1 Aug 2017.
    • 25 Apr 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Jul 2017.
    • 25 Apr 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top